Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...

Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Jasper Therapeutics Inc (JSPR) stock saw a decline, ending the day at $6.99 which represents a decrease of $-10.72 or -60.53% from the prior close of $17.71. The stock opened at $8.74 and touched a ...

Citi keeps a Buy rating on Celldex (CLDX) with a $70 price target after after Jasper Therapeutics (JSPR) reported preliminary data from its ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...

On Wednesday, Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous ...